Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiopulmonary revenue shifts, FDA trial updates, and executive stock sales all hide deep inside LivaNova’s SEC documents. For a medical-device maker whose fortunes depend on heart-lung machines and vagus-nerve stimulators, every line of a 10-K matters—and parsing it can consume days.
Stock Titan solves that problem. Our AI reads each LivaNova annual report 10-K simplified, every LivaNova quarterly earnings report 10-Q filing, and the continuous stream of LivaNova 8-K material events explained, extracting plain-English summaries and key metrics. Real-time alerts surface LivaNova insider trading Form 4 transactions so you can track LivaNova Form 4 insider transactions real-time without refreshing EDGAR. Need to evaluate pay packages? The platform highlights clauses inside the LivaNova proxy statement executive compensation.
Use cases include:
- Comparing segment margins across cardiopulmonary and neuromodulation with our LivaNova earnings report filing analysis.
- Monitoring clinical-trial disclosures to gauge pipeline timing.
- Flagging executive stock transactions Form 4 before earnings calls.
Whether you’re a portfolio manager assessing reimbursement risk or an analyst understanding LivaNova SEC documents with AI, every filing—10-K, 10-Q, 8-K, S-8, or SC 13G—arrives here within minutes of hitting EDGAR. Clean HTML, downloadable PDFs, and one-click AI highlights mean LivaNova SEC filings explained simply, so you spend time on decisions, not document hunts.
LivaNova director Francesco Bianchi sold 1,500 ordinary shares on 08/25/2025 at a reported price of $56.50 per share. After the sale he beneficially owned 9,028 ordinary shares, reported as direct ownership. The Form 4 was signed on behalf of the reporting person by Sarah K. Mohr, Attorney-in-Fact, on 08/27/2025. The filing discloses the transaction code S (sale) and provides the reporter's London address; no derivative transactions or amendments are reported.
LivaNova PLC (LIVN) submitted a Form 144 notice reporting a proposed sale of 1,500 ordinary shares through Merrill Lynch with an aggregate market value of $84,750. The shares were acquired on 06/29/2021 upon vesting of a restricted stock unit award granted under the issuer's equity compensation plan. The filer indicates the approximate date of sale as 08/25/2025 and the intended exchange is NASDAQ. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer and references Rule 144 and Rule 10b5-1 trading plan considerations.
LivaNova PLC (LIVN) Q2-25 10-Q highlights:
- Net revenue rose 10.6% YoY to $352.5 m; six-month revenue up 9.1% to $669.4 m.
- Gross margin held steady at 67.8%; operating income jumped 34.9% to $54.2 m on disciplined SG&A (+10.1%) and R&D spend (-7.9%).
- GAAP EPS improved to $0.50 versus $0.30; diluted share count 54.7 m.
- Six-month results swung to a $300.2 m loss after booking a $362.1 m SNIA environmental charge.
- Cash climbed to $593.6 m (-$130 m q-o-q after releasing $294.7 m restricted cash); total debt reduced 31% to $430.6 m following a $200 m early term-loan repayment.
- SNIA litigation reserve now $392.3 m; €270 m surety bond in place pending appeal. Cyber-incident costs reached $13 m, with $9.6 m insurance recovery to date.
- Liquidity: $225 m revolver undrawn; operating cash flow +63% YoY to $86.9 m H1-25.
- No covenant breaches; capped-call and embedded derivatives re-measured, neutral P&L effect.
Management reaffirmed focus on core Cardiopulmonary & Neuromodulation segments and continues restructuring begun 2024. Litigation and environmental exposures remain the key overhang despite solid operating momentum and deleveraging.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
